American Diabetes Association's 83rd Scientific Sessions recently concluded at the San Diego Conference Center in San Diego, California, USA, held from June 23-26, 2023. As one of the largest diabetes conferences globally, the conference drew over 12,000 esteemed physicians, scientists, and healthcare professionals from various parts of the world. This significant event showcased cutting-edge scientific breakthroughs in the diabetes field, encompassing more than 90 scientific sessions and featuring over 2,000 original research presentations¹.

Throughout the exhibition, Gan & Lee Pharmaceuticals' booth attracted experts, scholars, media representatives, doctors, and individuals associated with the diabetes field from various countries. This engagement helped enhance industry insiders' comprehension of Gan & Lee's current standing. One attendee expressed his delight, stating, "I am pleased to witness Gan & Lee's enduring dedication and profound commitment to the diabetes field. It is gratifying to see a Chinese company taking the stage at ADA to represent the voice of China.”

In the medical information area, Gan & Lee's team prominently showcased the company's drug pipeline for the international market. The team also provided insights into the published clinical data that supports the company's Biologics License Application (BLA) at US FDA, thus laying a favorable and efficient groundwork for the subsequent launch of relevant products in the United States.

Gan & Lee's insulin and device products have been launched in nearly 20 countries spanning four continents. Notably, this year, the company has received BLA acceptance from the U.S. FDA on its three core products – Insulin Glargine, Lispro, and Aspart. The three BLAs have entered the substantive review stage, and Gan & Lee will do their best to facilitate the approval in the U.S. and Europe. By actively expanding the product reach into diverse global markets, Gan & Lee strongly believes in fostering strong connections with the global diabetes community and extending the benefits of their products to a greater number of patients worldwide.

References:

1.American Diabetes Association. (2023, June 19). The American Diabetes Association commences its 83rd scientific sessions to showcase game changing diabetes advances. The American Diabetes Association Commences its 83rd Scientific Sessions to Showcase Game Changing Diabetes Advances | ADA. https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-commences-83rd-scientific-sessions-showcase-diabetes-advances

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.